查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018723

視網膜疾病治療市場：治療方法、給藥途徑、適應症、最終用戶和分銷管道分類－2026-2032年全球市場預測

Retinal Disorder Treatment Market by Treatment Modality, Route Of Administration, Disease Indication, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年視網膜疾病治療市場價值為 141.5 億美元，預計到 2025 年將成長至 152.2 億美元，複合年成長率為 8.01%，到 2032 年將達到 262.1 億美元。

主要市場統計數據
基準年 2024 141.5億美元
預計年份：2025年 152.2億美元
預測年份 2032 262.1億美元
複合年成長率 (%) 8.01%

對整體情況創新和策略優先順序的新治療模式和未滿足的需求進行了引人入勝的概述。

視網膜疾病仍然是視力障礙和醫療負擔的主要原因，其治療格局正受到科學創新、監管變化和醫療服務模式轉型的影響而迅速發展。本文旨在為相關人員提供策略背景，幫助他們了解臨床需求與技術可能性之間的交匯點，以及未來幾年投資和營運選擇的關鍵所在。

生物製劑、數位診斷、分散式交付模式和加速監管方面的進步，正在重塑視網膜醫學，並帶來重大轉折點。

在視網膜醫學領域，變革正在發生，它正在改變治療方法的發現、實施和評估方式。分子生物學和遞送技術的進步正推動該領域從短期玻璃體內注射轉向長效製劑和針對疾病潛在機制的新型治療方法。同時，包括人工智慧影像分析在內的數位診斷技術正在簡化病例檢測、分流和監測流程，從而實現早期療育和更精確的治療效果評估。

評估美國到 2025 年的累積關稅將如何重塑供應鏈、製造選擇、定價方式和病患取得途徑。

到2025年，美國將逐步實施一系列關稅，其累積影響對整個視網膜治療價值鏈上的製造商、經銷商和醫療服務提供者提出了至關重要的戰略考量。關稅帶來的成本壓力正在影響製造地的選擇、採購合約的結構以及旨在實現成本、品質和應對力之間最佳平衡的籌資策略的發展。因此，各機構正在重新評估其供應商佈局，並探索近岸外包和多元化經營，以維持供應的連續性並降低利潤率波動。

從疾病類型、藥物類別、給藥途徑、最終用戶和分銷管道等方面的策略洞察，指導策略性細分的選擇。

視網膜疾病涵蓋多種病理、治療方法、給藥技術、臨床環境和通路；因此，進行有效的細分對於使研發和商業化策略與臨床實踐和支付方的期望保持一致至關重要。疾病細分包括老齡化黃斑部病變（本身又分為乾性和濕性兩種）、糖尿病視網膜病變（可分為非增殖期和增殖期）以及視網膜靜脈阻塞（表現為分支靜脈阻塞和中央靜脈阻塞等亞型）。這些臨床差異導致終點指標、監測要求和治療頻率的不同，這些差異必須在臨床試驗設計和標籤策略中反映出來。

針對美洲、歐洲、中東和非洲以及亞太地區的區域影響和臨床准入情況進行研究，以指導市場准入和合作關係。

區域趨勢對視網膜治療領域的臨床應用、報銷機制、供應鏈物流和合作機會都具有至關重要的影響。在美洲，由於由專科診所、門診手術中心和綜合醫療保健系統組成的生態系統，這些系統促進了先進療法的普及，新型生物製藥和植入式醫療設備在臨床實踐中的應用呈現快速成長的趨勢。該地區的監管路徑和與支付方的談判都強調真實世界數據（REW）以及高成本、長期治療方法的衛生經濟學論點。

競爭格局分析和策略定位分析重點在於創新管道、合作模式、生物相似藥參與企業和生產靈活性。

視網膜治療領域的主要企業正將資源投入多個策略領域，包括新一代生物製劑、長效給藥平台、細胞和基因療法以及診斷技術的整合。夥伴關係地位日益不僅體現在產品療效和安全性上，還體現在證據生成能力、供應鏈可靠性以及包括契約製造製造商、專業經銷商和臨床服務供應商在內的合作夥伴生態系統上。

為產業領導者提供具體建議，以加速治療藥物研發、最佳化治療途徑、降低生產風險並改善臨床療效。

行業領導者應優先考慮一系列有針對性的舉措，以在確保患者用藥和業務永續營運的同時，獲得臨床和商業性價值。首先，研發項目應與具有臨床意義的終點和實際可行性一致，確保試驗設計能夠產生可供支付方和醫療服務提供者做出明智決策的數據。其次，應投資於緩釋技術和替代給藥途徑，因為臨床證據表明，這些技術能夠顯著減輕治療負擔，而這些特性正日益影響臨床醫生和患者的接受度。

透過對專家進行訪談、針對性的文獻綜述、監管分析和多階段檢驗等調查方法，得出實用見解。

本研究採用結構化、多維度的方法，旨在得出基於實證且具有實踐意義的見解。研究人員對臨床專業人員、商業領袖、監管顧問和供應鏈專家進行了有針對性的訪談，以了解從業人員的觀點並檢驗其策略意義。此外，研究人員還透過有針對性的文獻綜述和對同行評審的臨床研究、監管公告以及公開指南的評估，整合了科學和政策趨勢。

簡明扼要地整合了視網膜疾病治療的策略意義、未滿足的需求以及改善患者預後的關鍵因素。

總之，視網膜疾病的治療正處於轉折點，科學進步、給藥方式創新以及政策環境的變化正在重新定義影響患者的治療路徑。滿足未被滿足的需求不僅需要突破性的科學進展，還需要兼顧市場區隔、區域趨勢和供應鏈實際情況的切實可行的策略。將臨床證據的累積與靈活的商業性和營運規劃相結合的相關人員，將更有利於確保治療方法的推廣應用並維持患者的可及性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 視網膜疾病治療市場（依治療方法分類）

  • 藥物治療（藥品）
    • 抗 VEGF
    • 皮質類固醇
  • 醫療器材與設備
    • 手術器械
    • 雷射設備
    • 診斷和影像設備
    • 植入

第9章 視網膜疾病治療市場：依給藥途徑分類

  • 玻璃體內注射
  • 口服
  • 視網膜下

第10章：視網膜疾病治療市場：依疾病適應症分類

  • 黃斑部病變
    • 老齡化黃斑部病變）
    • 濕性老齡化黃斑部病變
  • 糖尿病視網膜病變
    • 不繁殖
    • 增殖
  • 視網膜靜脈阻塞
    • 分支靜脈阻塞
    • 中心靜脈阻塞
  • 葡萄膜炎

第11章 視網膜疾病治療市場：依最終使用者分類

  • 門診手術中心
  • 專科診所
  • 家庭醫療保健
  • 醫院

第12章 視網膜疾病治療市場：依通路分類

  • 離線
    • 醫院藥房
    • 零售藥房
  • 線上

第13章 視網膜疾病治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 視網膜疾病治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 視網膜疾病治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國視網膜疾病治療市場

第17章 中國視網膜疾病治療市場

第18章 競爭格局

  • 2024年市場集中度分析
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2024 年
  • 2024年產品系列分析
  • 基準分析，2024 年
  • AbbVie Inc.
  • Amgen Inc.
  • Apellis Pharmaceuticals, Inc.
  • Bausch+Lomb Corporation
  • Bayer AG
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • REGENERON PHARMACEUTICALS, INC.
  • Sandoz Group AG
  • Sanofi SA
Product Code: MRR-CA17E905E6E9

The Retinal Disorder Treatment Market was valued at USD 14.15 billion in 2024 and is projected to grow to USD 15.22 billion in 2025, with a CAGR of 8.01%, reaching USD 26.21 billion by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 14.15 billion
Estimated Year [2025] USD 15.22 billion
Forecast Year [2032] USD 26.21 billion
CAGR (%) 8.01%

Compelling overview of emerging therapeutic paradigms and unmet needs driving innovation and strategic prioritization across retinal disorder treatment landscape

Retinal disorders remain a primary cause of vision impairment and healthcare burden, and the therapeutic landscape is evolving rapidly under the influence of scientific innovation, regulatory change, and shifting care delivery models. This introduction frames the strategic context for stakeholders seeking to understand where clinical need intersects with technological possibility, and where investment and operational choices will matter most in the coming years.

Progress in biologics, sustained-release implants, gene and cell therapies, and diagnostic algorithms has expanded the menu of therapeutic options, but it has also increased complexity in clinical pathways and commercialization planning. Clinicians are integrating new treatment modalities into long-established protocols, payers are re-evaluating value constructs as outcomes data matures, and manufacturers must balance innovation with pragmatic considerations such as supply chain resilience and site-of-care suitability.

Consequently, this executive summary synthesizes the critical drivers shaping research and commercial strategies across retinal indications. It spotlights technological and policy shifts that influence development decisions and market access approaches, and it clarifies how stakeholders can position themselves to accelerate patient benefit while managing regulatory, operational, and economic risks.

Key inflection points reshaping retinal care through biologics evolution, digital diagnostics, decentralized delivery models, and regulatory acceleration

The retinal care landscape is undergoing transformative shifts that alter how therapies are discovered, delivered, and valued. Advances in molecular biology and delivery technologies have moved the field beyond short-interval intravitreal injections toward longer-acting formulations and novel modalities that target underlying disease mechanisms. At the same time, digital diagnostics, including artificial intelligence-enabled image analysis, are streamlining case detection, triage, and monitoring, enabling earlier intervention and more precise outcome measurements.

Care delivery models are decentralizing as ambulatory surgical centers and clinic-based injections expand their role, and as home healthcare solutions for chronic monitoring and adherence support gain traction. Payer expectations are evolving in parallel, with an increased focus on real-world outcomes, total cost of care, and the ability to demonstrate durable benefit. Regulatory pathways have adapted to faster approvals for breakthrough therapies and innovative delivery systems, increasing the need for robust post-marketing evidence generation.

Together, these shifts create both opportunity and complexity. Companies that integrate translational science with pragmatic commercial planning, adopt data-driven value demonstration strategies, and design flexible supply chains will capture advantage. Conversely, actors that treat these changes as incremental risk will face pressure from more agile competitors and changing stakeholder expectations.

Assessment of how cumulative United States tariffs through 2025 are reshaping supply chains, manufacturing choices, pricing approaches, and patient access

The cumulative effect of tariffs implemented in the United States by 2025 introduces material strategic considerations for manufacturers, distributors, and providers across the retinal therapy value chain. Tariff-driven cost pressures are influencing decisions about where to locate manufacturing, how to structure procurement contracts, and which sourcing strategies will deliver the best balance of cost, quality, and responsiveness. As a result, organizations are reassessing supplier footprints and evaluating nearshoring or diversification to maintain supply continuity and control margin volatility.

Procurement teams and commercial leaders are recalibrating pricing approaches and contractual terms to preserve access while remaining commercially viable. Payers and health systems are sensitive to cost trends, which amplifies the need for strong evidence of clinical value and for alternative contracting models that link payment to outcomes. In parallel, import tariffs can slow throughput of specialized components and finished products, prompting manufacturers to increase inventory buffers, qualify alternate suppliers, or adjust lead times for high-value biologics and implantable delivery systems.

Regulatory and market access functions must therefore coordinate closely with manufacturing and commercial operations to articulate the impact of tariff-related changes on timelines for product availability and to develop mitigations that protect patient access. Proactive scenario planning, supplier risk assessment, and investment in supply chain transparency will be central to maintaining operational resilience in a tariff-influenced environment.

Strategic insights across disease types, drug classes, administration routes, end users, and distribution channels guiding strategic segmentation choices

Meaningful segmentation is essential for aligning development and commercialization strategies with clinical practice and payer expectations, because retinal disorders encompass diverse disease states, therapeutic modalities, administration techniques, care settings, and distribution pathways. The disease segmentation spans Age-Related Macular Degeneration, which itself divides into dry and wet forms, Diabetic Retinopathy, observed in nonproliferative and proliferative stages, and Retinal Vein Occlusion, which manifests as branch and central vein occlusion variants. These clinical distinctions drive differing endpoints, monitoring requirements, and treatment frequencies, and they must inform trial design and labeling strategies.

Drug class segmentation delineates anti-VEGF therapies and corticosteroids as core therapeutic families. Within anti-VEGF agents, commonly used molecules include aflibercept, bevacizumab, brolucizumab, and ranibizumab, each with distinct pharmacologic profiles and evidence bases that affect dosing intervals and safety monitoring. Corticosteroid options such as dexamethasone implants, fluocinolone acetonide, and triamcinolone acetonide provide alternative mechanisms and delivery durations that are relevant for steroid-responsive disease or cases where anti-VEGF is inadequate.

Route of administration is another critical lens, encompassing intravitreal injection as the dominant current approach, alongside oral, subretinal, and topical routes that reflect emerging technologies and patient-centric delivery innovations. End user segmentation differentiates ambulatory surgical centers, clinics-both multispecialty and ophthalmology-specific-home healthcare services, and hospital settings including inpatient and outpatient units; each end user type has distinct operational capabilities, reimbursement considerations, and capacity for administering complex interventions. Finally, distribution channels range from hospital pharmacies to online pharmacies and retail pharmacies, shaping how therapies reach patients and how logistical, regulatory, and adherence considerations are managed.

Integrated segmentation analysis reveals where clinical need, therapeutic attributes, and delivery realities converge to create differentiated value propositions. For example, an extended-duration anti-VEGF agent will intersect favorably with ambulatory surgical centers and ophthalmology clinics that prioritize reduced visit frequency, whereas cell- or gene-based subretinal therapies will require coordinated hospital-based surgical capacity and intensive post-procedural monitoring. Understanding these intersections enables more targeted clinical development plans, tailored reimbursement submissions, and pragmatic launch strategies that account for both clinical workflow and patient experience.

Region-focused implications and clinical access considerations across Americas, Europe Middle East & Africa, and Asia-Pacific to guide market entry and alliances

Regional dynamics exert a critical influence on clinical adoption, reimbursement frameworks, supply chain logistics, and partnership opportunities across the retinal therapy landscape. In the Americas, clinical practice often reflects rapid adoption of novel biologics and implantable devices, supported by an ecosystem of specialized clinics, ambulatory surgical centers, and integrated health systems that facilitate access to advanced interventions. Regulatory pathways and payer negotiations in this region emphasize real-world evidence and health economic justification for higher-cost, durable therapies.

In Europe, the Middle East and Africa, heterogeneous healthcare infrastructures and diverse reimbursement systems create a mosaic of adoption pathways. Some markets demonstrate rapid uptake of new therapeutics where payer systems enable coverage for high-value interventions, whereas other markets require adaptive pricing and access strategies. Local manufacturing, partnership models, and supplier relationships can be decisive in overcoming distribution barriers and in tailoring educational programs for clinicians and patients.

The Asia-Pacific region presents a combination of high-volume demand, rapidly modernizing clinical capacity, and significant variation in regulatory environments. Several markets in this region have invested heavily in ophthalmic infrastructure and in digital screening programs, enabling earlier detection and treatment initiation. However, differences in procurement practices, hospital funding models, and patient payment structures necessitate nuanced commercialization planning. Across regions, cross-border manufacturing and tariff considerations, alongside regional clinical trial capacity, will shape where and how companies prioritize launches and scale operations.

Competitive profiling and strategic positioning analysis highlighting innovation pipelines, partnership models, biosimilar entrants, and manufacturing agility

Leading companies in the retinal therapeutics space are allocating resources across multiple strategic fronts, including next-generation biologics, long-acting delivery platforms, cell and gene approaches, and diagnostics integration. Competitive positioning increasingly reflects not only product efficacy and safety, but also capabilities in evidence generation, supply chain reliability, and partnership ecosystems that include contract manufacturers, specialty distributors, and clinical service providers.

Pipeline dynamics show a mixture of incremental innovation-such as dosing interval extension and implant refinements-and disruptive approaches that aim to reduce treatment burden or to modify disease progression. Firms that successfully integrate real-world evidence collection into launch planning are better equipped to negotiate value-based contracts and to demonstrate comparative effectiveness in diverse care settings. Partnerships and licensing agreements are important levers for accelerating development timelines and for securing manufacturing scale, with many organizations leveraging collaborative models to combine scientific expertise with commercial reach.

Operational agility, including the capacity to adapt manufacturing footprints and to adopt alternative distribution arrangements, is becoming a differentiator. Companies that build modular supply chains, invest in cold-chain visibility, and engage early with key clinical sites can shorten time-to-adoption and reduce rollout friction. Finally, strategic attention to clinician education and patient support programs complements product performance by facilitating proper use and adherence, thereby supporting longer-term clinical and commercial success.

Focused recommendations for industry leaders to accelerate therapeutic development, optimize access, de-risk manufacturing, and improve clinical outcomes

Industry leaders should prioritize a set of targeted actions to capture clinical and commercial value while protecting patient access and operational continuity. First, align R&D programs with clinically meaningful endpoints and real-world feasibility to ensure that trial designs produce data that payers and providers will use in decision making. Second, invest in extended-duration delivery technologies and alternative administration routes where clinical evidence suggests meaningful reductions in treatment burden, because these features increasingly influence adoption among clinicians and patients.

Third, strengthen supply chain resilience by diversifying suppliers, qualifying regional manufacturing capabilities, and embedding inventory and logistics flexibility to mitigate tariff and trade-related disruptions. Fourth, build robust evidence-generation programs that combine randomized controlled data with real-world outcome collection and health economic analyses; this integrated approach supports pricing negotiations and value-based contracting. Fifth, develop end-user-focused rollouts that account for the operational nuances of ambulatory surgical centers, clinic environments, home healthcare models, and hospital systems; tailoring training, scheduling, and reimbursement navigation will improve uptake and patient experience.

Finally, cultivate strategic partnerships across the ecosystem, including diagnostics firms, contract manufacturers, clinical service organizations, and payers. Such collaborations can accelerate access to complementary capabilities, reduce time to market, and enable innovative contracting that aligns payment with outcomes. Executed together, these actions will help organizations accelerate therapeutic development, optimize patient access, and de-risk commercial execution.

Methodological approach using expert interviews, targeted literature review, regulatory analysis, and multi-step validation to produce actionable insights

This research applied a structured, multi-method approach to develop findings that are evidence-based and operationally relevant. We conducted targeted interviews with clinical experts, commercial leaders, regulatory advisors, and supply chain specialists to capture practitioner perspectives and to validate strategic implications. In addition, a targeted literature review and appraisal of peer-reviewed clinical studies, regulatory announcements, and publicly available guidance informed the synthesis of scientific and policy trends.

The analysis also incorporated a review of clinical practice patterns and care setting capabilities to align therapeutic attributes with real-world delivery models. Where appropriate, triangulation across expert input, published clinical evidence, and operational considerations was used to validate conclusions and to surface practical recommendations. Multi-step validation included cross-functional review to ensure the insights are actionable for stakeholders involved in development, manufacturing, market access, and commercialization.

Concise synthesis of strategic implications, persistent unmet needs, and the critical levers for advancing patient outcomes in retinal disorder therapeutics

In conclusion, the retinal disorder treatment landscape is at an inflection point where scientific progress, delivery innovation, and shifting policy environments jointly redefine the pathways to patient impact. Addressing unmet clinical needs requires not only breakthrough science but also pragmatic strategies that account for segmentation, regional dynamics, and supply chain realities. Stakeholders that integrate clinical evidence generation with flexible commercial and operational planning will be better positioned to secure adoption and to sustain access.

Persistent needs around treatment durability, patient convenience, and equitable access will continue to shape investment priorities. At the same time, tariff pressures and evolving reimbursement expectations underscore the importance of preparedness across manufacturing, procurement, and payer engagement. By aligning development priorities with end-user capabilities and regional nuances, organizations can accelerate translation from lab to clinic and deliver therapies that meaningfully improve patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2024
  • 3.5. FPNV Positioning Matrix, 2024
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Retinal Disorder Treatment Market, by Treatment Modality

  • 8.1. Pharmacotherapy (Drugs)
    • 8.1.1. Anti-VEGF
    • 8.1.2. Corticosteroids
  • 8.2. Devices & Instruments
    • 8.2.1. Surgical Devices
    • 8.2.2. Laser Devices
    • 8.2.3. Diagnostic & Imaging Devices
    • 8.2.4. Implants

9. Retinal Disorder Treatment Market, by Route Of Administration

  • 9.1. Intravitreal Injection
  • 9.2. Oral
  • 9.3. Subretinal

10. Retinal Disorder Treatment Market, by Disease Indication

  • 10.1. Macular Degeneration
    • 10.1.1. Dry Age-Related Macular Degeneration
    • 10.1.2. Wet Age-Related Macular Degeneration
  • 10.2. Diabetic Retinopathy
    • 10.2.1. Nonproliferative
    • 10.2.2. Proliferative
  • 10.3. Retinal Vein Occlusion
    • 10.3.1. Branch Vein Occlusion
    • 10.3.2. Central Vein Occlusion
  • 10.4. Uveitic Disease

11. Retinal Disorder Treatment Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Specialized Clinics
  • 11.3. Home Healthcare
  • 11.4. Hospitals

12. Retinal Disorder Treatment Market, by Distribution Channel

  • 12.1. Offline
    • 12.1.1. Hospital Pharmacy
    • 12.1.2. Retail Pharmacy
  • 12.2. Online

13. Retinal Disorder Treatment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Retinal Disorder Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Retinal Disorder Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Retinal Disorder Treatment Market

17. China Retinal Disorder Treatment Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2024
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2024
  • 18.3. Product Portfolio Analysis, 2024
  • 18.4. Benchmarking Analysis, 2024
  • 18.5. AbbVie Inc.
  • 18.6. Amgen Inc.
  • 18.7. Apellis Pharmaceuticals, Inc.
  • 18.8. Bausch + Lomb Corporation
  • 18.9. Bayer AG
  • 18.10. F. Hoffmann-La Roche Ltd
  • 18.11. Novartis AG
  • 18.12. REGENERON PHARMACEUTICALS, INC.
  • 18.13. Sandoz Group AG
  • 18.14. Sanofi SA

LIST OF FIGURES

  • FIGURE 1. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RETINAL DISORDER TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 3. GLOBAL RETINAL DISORDER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 4. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA RETINAL DISORDER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY PHARMACOTHERAPY (DRUGS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY PHARMACOTHERAPY (DRUGS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY PHARMACOTHERAPY (DRUGS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY PHARMACOTHERAPY (DRUGS), 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVICES & INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVICES & INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVICES & INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVICES & INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY SURGICAL DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY SURGICAL DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY SURGICAL DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY LASER DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY LASER DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY LASER DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DIAGNOSTIC & IMAGING DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DIAGNOSTIC & IMAGING DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DIAGNOSTIC & IMAGING DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY SUBRETINAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY SUBRETINAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY SUBRETINAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DRY AGE-RELATED MACULAR DEGENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DRY AGE-RELATED MACULAR DEGENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DRY AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY WET AGE-RELATED MACULAR DEGENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY WET AGE-RELATED MACULAR DEGENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY WET AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY NONPROLIFERATIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY NONPROLIFERATIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY NONPROLIFERATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY PROLIFERATIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY PROLIFERATIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY PROLIFERATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY BRANCH VEIN OCCLUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY BRANCH VEIN OCCLUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY BRANCH VEIN OCCLUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY CENTRAL VEIN OCCLUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY CENTRAL VEIN OCCLUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY CENTRAL VEIN OCCLUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY UVEITIC DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY UVEITIC DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY UVEITIC DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY SPECIALIZED CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY SPECIALIZED CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY PHARMACOTHERAPY (DRUGS), 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVICES & INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, BY PHARMACOTHERAPY (DRUGS), 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVICES & INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, BY PHARMACOTHERAPY (DRUGS), 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVICES & INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA RETINAL DISORDER TREATMENT MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY PHARMACOTHERAPY (DRUGS), 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVICES & INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE RETINAL DISORDER TREATMENT MARKET SIZE, BY PHARMACOTHERAPY (DRUGS), 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVICES & INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE RETINAL DISORDER TREATMENT MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST RETINAL DISORDER TREATMENT MARKET SIZE, BY PHARMACOTHERAPY (DRUGS), 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVICES & INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST RETINAL DISORDER TREATMENT MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY PHARMACOTHERAPY (DRUGS), 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVICES & INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY PHARMACOTHERAPY (DRUGS), 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVICES & INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN RETINAL DISORDER TREATMENT MARKET SIZE, BY PHARMACOTHERAPY (DRUGS), 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVICES & INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN RETINAL DISORDER TREATMENT MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 210. GCC RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. GCC RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 212. GCC RETINAL DISORDER TREATMENT MARKET SIZE, BY PHARMACOTHERAPY (DRUGS), 2018-2032 (USD MILLION)
  • TABLE 213. GCC RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVICES & INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 214. GCC RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 215. GCC RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 216. GCC RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2032 (USD MILLION)
  • TABLE 217. GCC RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2032 (USD MILLION)
  • TABLE 218. GCC RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 219. GCC RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. GCC RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. GCC RETINAL DISORDER TREATMENT MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION RETINAL DISORDER TREATMENT MARKET SIZE, BY PHARMACOTHERAPY (DRUGS), 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVICES & INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION RETINAL DISORDER TREATMENT MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS RETINAL DISORDER TREATMENT MARKET SIZE, BY PHARMACOTHERAPY (DRUGS), 2018-2032 (USD MILLION)
  • TABLE 237. BRICS RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVICES & INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS RETINAL DISORDER TREATMENT MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 246. G7 RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. G7 RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 248. G7 RETINAL DISORDER TREATMENT MARKET SIZE, BY PHARMACOTHERAPY (DRUGS), 2018-2032 (USD MILLION)
  • TABLE 249. G7 RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVICES & INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 250. G7 RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 251. G7 RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 252. G7 RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2032 (USD MILLION)
  • TABLE 253. G7 RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2032 (USD MILLION)
  • TABLE 254. G7 RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 255. G7 RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. G7 RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 257. G7 RETINAL DISORDER TREATMENT MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 258. NATO RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. NATO RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 260. NATO RETINAL DISORDER TREATMENT MARKET SIZE, BY PHARMACOTHERAPY (DRUGS), 2018-2032 (USD MILLION)
  • TABLE 261. NATO RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVICES & INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 262. NATO RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 263. NATO RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 264. NATO RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2032 (USD MILLION)
  • TABLE 265. NATO RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2032 (USD MILLION)
  • TABLE 266. NATO RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 267. NATO RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 268. NATO RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 269. NATO RETINAL DISORDER TREATMENT MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 270. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY PHARMACOTHERAPY (DRUGS), 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVICES & INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA RETINAL DISORDER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA RETINAL DISORDER TREATMENT MARKET SIZE, BY PHARMACOTHERAPY (DRUGS), 2018-2032 (USD MILLION)
  • TABLE 286. CHINA RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVICES & INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR DEGENERATION, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA RETINAL DISORDER TREATMENT MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)